药物洗脱支架时代再狭窄的预防和治疗

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (11): 1201-1207.

• 专论 • 下一篇

药物洗脱支架时代再狭窄的预防和治疗

柯永胜, 高文俊, 胡学俊

皖南医学院心血管疾病研究所皖南医学院弋矶山医院心内科, 芜湖 241001, 安徽

收稿日期:2008-10-06 修回日期:2008-11-10 出版日期:2008-11-26 发布日期:2020-10-14
作者简介:柯永胜, 男, 主任医师, 教授。皖南医学院硕士研究生导师(病理生理学、心血管内科学) 。在国内外各级刊物发表学术论文130 余篇, 其中在SCI 收录期刊发表学术论文7 篇, 出版学术专著5 部, 系安徽省学术与技术带头人培养对象, 安徽省教育厅学术与技术带头人培养对象、安徽省卫生厅学术与技术带头人培养对象, 国家自然科学基金同行评议专家。Journal of Pharmacology and Experimental Therapeutics、International Journal of Cardiology、Acta Pharmacologica Sinica、Acta Clin Chemica、Biochemical Pharmacology、Journal of the College of Physicians and Surgeons Pakistan 、中国药理学通报、皖南医学院学报等杂志审稿人。中国临床药理学与治疗学杂志编委, 西安交通大学学报医学版特约编委。享受安徽省政府特殊津贴。专业方向:冠心病介入治疗, 心肌缺血再灌注机制研究。Tel: 0553-5739313 E-mail: kongyongsheng@163.com

Prevention and treatment of restenosis in era of drug-eluting stent

KE Yong-sheng, GAO Wen-jun, HU Xue-jun

Department of Cardiology, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China;
Institute of Cardiovascular Disease, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2008-10-06 Revised:2008-11-10 Online:2008-11-26 Published:2020-10-14

摘要/Abstract

摘要： 药物洗脱支架有效地降低了再狭窄的发生率,扩大了冠脉介入治疗的领域。然而,随着介入治疗的病变越来越复杂,病例越来越多,其本身的再狭窄问题也变得令人瞩目。如何处理药物洗脱支架后的支架内再狭窄,已经成为心脏病学面临的新挑战。本文就药物洗脱支架再狭窄的原因、特点、预测因素、治疗策略作一综述。

关键词: 药物洗脱支架, 再狭窄/支架, 治疗

Abstract: Drug-eluting stent ( DES) could effectively decrease the rate of restenosis of percutaneous coronary intervention ( PCI) and extend scope of PCI. However, the restenosis of DES is a focus with complex lesion and samples more and more. It had become the new challenge of treating restenosis of DES. This paper reviews the causes, characteristic, prognosis factors and treatment strategy.

Key words: drug-eluting stent, restenosis stent, treatment

中图分类号:

R541.4

柯永胜, 高文俊, 胡学俊. 药物洗脱支架时代再狭窄的预防和治疗[J]. 中国临床药理学与治疗学, 2008, 13(11): 1201-1207.

KE Yong-sheng, GAO Wen-jun, HU Xue-jun. Prevention and treatment of restenosis in era of drug-eluting stent[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1201-1207.

参考文献

[1] Moses JW, LeonMB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patientswith stenosis in a native coronary artery[J]. N Engl J Med, 2003, 349(14): 1315-1323.
[2] AbalM, Andreu JM, Barasoain I, et al. Taxanes:microtubule and centrosome targets, and cell cycle dependent mechanisms of action[J]. Curr Cancer Drug Targets, 2003, 3(3): 193-203.
[3] Sherr CJ, Roberts JM.CDK inhibitors: positive and negative regulators of G₁ phase progression[J]. Genes Dev, 1999, 13(12): 1501-1512.
[4] Holmes DR, LeonMB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial.A randomized trial of a sirolimus-eluting stent versus a standared stent in patients at high risk for coronary restenosis[J]. Circulation, 2004, 109(5): 634-640.
[5] Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial[J]. JAMA, 2005, 294(10): 1215-1223.
[6] Rahel BM, Laarman GJ, Suttorp MJ, et al. Primary stenting of occluded native coronary arteries II-rationale and design of the PRISON II study: a randomized comparison of baremetal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions[J]. Am Heart J, 2005, 149(3): 1-3.
[7] Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation[J]. J Am Coll Cardiol, 2005, 45(3): 351-356.
[8] Dibra A, KastratiA, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients[J]. N Engl JMed, 2005, 353(7): 663-670.
[9] Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions[J]. Circulation, 2004, 109(10): 1244-1249.
[10] Chieffo A, Stankovic G, Bonizzoni E, et al. Early and midterm results of drug-eluting stent implantation in unprotected left main[J]. Circulation, 2005, 111(6): 791-795.
[11] Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamy cin-eluting stent evaluated at rotterdam cardiology hospital(RESEARCH) study[J]. Circulation, 2004, 109(11): 1366-1370.
[12] Iakovou I, Schmidt T, Ge L, et al. Angiographic patterns of restenosis after paclitaxel-eluting stent implantation[J]. J Am Coll Cardiol, 2005, 45(5): 805-806.
[13] KastratiA, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents[J]. Circulation, 2006, 113(19): 2293-2300.
[14] Lee CW, Park DK, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries[J]. Am J Cardiol, 2006, 97(4): 506-511.
[15] Hong MK, Lee CW, Kim YH, et al. Intravascular ultrasound predictors and their cut-off values for angiographic restenosis after sirolimus-eluting stent implantation[J]. JACC, 2006, 47(4): 189A.
[16] Mauri L, O’Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents[J]. Am J Cardiol, 2005, 95(10): 1140-1145.
[17] Hong SJ, Kim MH, Ahn TH, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes[J]. Heart, 2006, 92(8): 1119-1124.
[18] Berenguer A, Mainar V, Bordes P, et al. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients[J]. Am Heart J, 2005, 150(3): 536-542.
[19] Takebay ashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation[J]. Am J Cardiol, 2005, 95(4): 498-502.
[20] Moussa ID, Moses JW, Kuntz RE, et al. The fate of patients with clinical recurrence after sirolimus-eluting stent implantation(a two-year follow-up analy sis from the SIRIUS trial)[J]. Am J Cardiol, 2006, 97(11): 1582-1584.
[21] Lemos PA, vanMieghem CA, Arampatzis CA, et al. Post sirolimus-eluting stent restenosis treated with repeat percutaneous intervention late angiographic and clinical outcomes[J]. Circulation, 2004, 109(21): 2500-2502.
[22] Ferri N, Granata A, Pirola C, et al. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1 cyclin E expression[J]. Mol Pharmacol, 2008, 74(1): 144-153.
[23] Sheiban I, Villata G, Bollati M, et al. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent[J]. Vasc Health Risk Manag, 2008, 4(1): 31-38.
[24] 张志民, 高艳霞, 刘怀霖, 等. 温通煎能预防冠心病患者介入治疗后再狭窄[J]. 中国动脉硬化杂志, 2006, 14(7): 610-613.
[25] 孟庆杰, 王阶, 吴荣.冠心病介入术后的中医药干预进展[J]. 中国中药杂志, 2008, 33(8): 962-964.

药物洗脱支架时代再狭窄的预防和治疗

Prevention and treatment of restenosis in era of drug-eluting stent

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[7]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[8]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[9]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[10]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[11]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[12]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[13]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[14]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[15]	党洋斌, 梁宇欣, 王天成. 进行性肌阵挛癫痫相关治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1184-1194.